Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints

Celldex Therapeutics, Inc.

2024-Q3 EPS reported -$1.74 revenue$5,845,000

Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.
Cash $756.0M as of Sep 30, 2024, down from $802.3M; expects to fund operations through 2027.
Barzolvolimab met all primary/secondary endpoints in Phase 2 CIndU; up to 57.6% complete response in SD.
Global Phase 3 CSU trials (EMBARQ-CSU1/2) actively enrolling; CIndU Phase 3 planned for 2025.
First bispecific CDX-622 (SCF/TSLP) entering Phase 1 in Q4 2024; CDX-585 development halted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.